WO1995033048A3 - P2x receptors (purinoceptor family) - Google Patents

P2x receptors (purinoceptor family) Download PDF

Info

Publication number
WO1995033048A3
WO1995033048A3 PCT/EP1995/001968 EP9501968W WO9533048A3 WO 1995033048 A3 WO1995033048 A3 WO 1995033048A3 EP 9501968 W EP9501968 W EP 9501968W WO 9533048 A3 WO9533048 A3 WO 9533048A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor
receptors
diseases
atp
prepared
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1995/001968
Other languages
French (fr)
Other versions
WO1995033048A2 (en
Inventor
Soledad Valera
Gary Nutter Buell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9410664A external-priority patent/GB9410664D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to AU25665/95A priority Critical patent/AU2566595A/en
Priority to JP8500271A priority patent/JPH10501122A/en
Priority to US08/750,134 priority patent/US5985603A/en
Priority to EP95920076A priority patent/EP0760850A1/en
Publication of WO1995033048A2 publication Critical patent/WO1995033048A2/en
Publication of WO1995033048A3 publication Critical patent/WO1995033048A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The P2X receptor of ATP has been cloned and expressed by recombinant DNA technology, so the receptor can be prepared free from other ATP receptors. The P2X receptor enables antibodies to be prepared and is useful in screening compounds for use in a variety of diseases and conditions, including epilepsy, cognition, emesis, pain (especially migraine), asthma, peripheral vascular disease, hypertension, diseases of the immune system, irritable bowel syndrome and premature ejaculation.
PCT/EP1995/001968 1994-05-27 1995-05-24 P2x receptors (purinoceptor family) Ceased WO1995033048A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU25665/95A AU2566595A (en) 1994-05-27 1995-05-24 P-2x receptors (purinoceptor family)
JP8500271A JPH10501122A (en) 1994-05-27 1995-05-24 P ▲ 2X ▼ receptor (purinoceptor family)
US08/750,134 US5985603A (en) 1994-05-27 1995-05-24 P2x receptor DNA and protein sequence
EP95920076A EP0760850A1 (en) 1994-05-27 1995-05-24 P2x RECEPTORS (PURINOCEPTOR FAMILY)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9410664A GB9410664D0 (en) 1994-05-27 1994-05-27 DNA sequences
GBGB9502480.8A GB9502480D0 (en) 1994-05-27 1995-02-09 DNA and protein sequences
GB9502480.8 1995-02-09
GB9410664.8 1995-02-09

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/363,745 Continuation US6194162B1 (en) 1994-05-27 1999-07-30 Method of screening for compounds that bind P2x receptor

Publications (2)

Publication Number Publication Date
WO1995033048A2 WO1995033048A2 (en) 1995-12-07
WO1995033048A3 true WO1995033048A3 (en) 1995-12-21

Family

ID=26304950

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1995/001968 Ceased WO1995033048A2 (en) 1994-05-27 1995-05-24 P2x receptors (purinoceptor family)

Country Status (5)

Country Link
US (2) US5985603A (en)
EP (1) EP0760850A1 (en)
JP (1) JPH10501122A (en)
AU (1) AU2566595A (en)
WO (1) WO1995033048A2 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2566595A (en) * 1994-05-27 1995-12-21 Glaxo Group Limited P-2x receptors (purinoceptor family)
JP2001521372A (en) * 1996-04-30 2001-11-06 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Human P2x4 receptor splice-variant
US5856129A (en) * 1996-10-30 1999-01-05 Incyte Pharmaceuticals, Inc. DNA encoding a human purinoceptor
DK1011686T3 (en) * 1997-03-25 2010-10-11 Duska Scient Co Modulation of human mast cell activation
JP3885177B2 (en) * 1997-03-26 2007-02-21 大塚製薬株式会社 Human gene
US6133434A (en) * 1997-04-28 2000-10-17 Glaxo Group Limited Purinergic receptor
US6228864B1 (en) 1997-10-28 2001-05-08 Vivus, Inc. Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation
US6037360A (en) * 1997-10-28 2000-03-14 Vivus, Incorporated Administration of 5-HT3 receptor antagonists to treat premature ejaculation
US5922341A (en) * 1997-10-28 1999-07-13 Vivus, Incorporated Local administration of pharmacologically active agents to treat premature ejaculation
US6242216B1 (en) 1997-11-14 2001-06-05 Abbott Laboratories Nucleic acids encoding a functional human purinoreceptor P2X2 and P2X4, and methods of production and use thereof
AU2206999A (en) * 1998-01-09 1999-07-26 Trustees Of The University Of Pennsylvania, The Compositions and methods for use in ischemia-reperfusion and endotoxin-related tissue injury
US6214581B1 (en) 1998-01-16 2001-04-10 Abbott Laboratories Nucleic acids encoding a functional human purinoreceptor P2X3 and P2X6, and methods of production and use thereof
EP1045903A1 (en) * 1998-01-16 2000-10-25 Abbott Laboratories Nucleic acids encoding a functional human purinoreceptor p2x3 and methods of production and use thereof
WO1999055901A2 (en) * 1998-04-30 1999-11-04 Abbott Laboratories Screening assay for identifying human purinoreceptor ligands
JP2002523043A (en) * 1998-08-20 2002-07-30 アボット・ラボラトリーズ Nucleic acids encoding functional human purine receptor P2X2 and methods for their production and use
AUPP991199A0 (en) 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
WO2001079561A2 (en) 2000-04-17 2001-10-25 Liggett Stephen B Alpha-2 adrenergic receptor polymorphisms
AUPQ968700A0 (en) * 2000-08-28 2000-09-21 Intreat Pty Limited Treatment of urinary incontinence
JP4384852B2 (en) 2001-01-17 2009-12-16 イントリート ピーティーワイ リミテッド Non-functional P2X7 receptor antibody, diagnosis and treatment of cancer and other conditions
WO2003040339A2 (en) * 2001-11-09 2003-05-15 Algos Therapeutics, Inc. Antisense modulation of purinoreceptor p2x¿3?
US20050181365A1 (en) * 2002-02-15 2005-08-18 Naik K. A. Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
US7211257B2 (en) 2003-02-10 2007-05-01 Rosalind Franklin University Of Medicine And Science Methods for inducing apoptosis in ovarian carcinoma cells using an anti-regeneration and tolerance factor antibody
JP2008507368A (en) * 2004-07-22 2008-03-13 デュスカ サイエンティフィック カンパニー Methods for diagnosing, monitoring and treating lung disease
CA2581086C (en) 2004-09-14 2023-11-07 The Regents Of The University Of Colorado, A Body Corporate Method for treatment with bucindolol based on genetic targeting
MX2008002014A (en) * 2005-08-15 2008-03-27 Hoffmann La Roche Piperidine and piperazine derivatives as p2x3 antagonists.
EP2038264B1 (en) * 2006-06-29 2016-10-26 F.Hoffmann-La Roche Ag Tetrazole-substituted arylamides
JP2010505426A (en) 2006-10-10 2010-02-25 バイオスセプター インターナショナル リミテッド Hybridoma producing antibody against non-functional P2X7 receptor
KR20100023040A (en) 2007-06-21 2010-03-03 쉐링 코포레이션 Polycyclic guanine derivatives and use thereof
ES2619681T3 (en) 2007-09-14 2017-06-26 Biosceptre (Aust) Pty Ltd Novel epitopes P2X7
ATE542139T1 (en) 2007-09-14 2012-02-15 Biosceptre Int Ltd PURINERGIC (P2X) RECEPTORS IN EXTRACELLULAR BODY FLUID
CN102143978B (en) 2008-07-04 2015-02-18 生物权威国际有限公司 Anti-P2X7 peptides and epitopes
EP2467404B1 (en) 2009-08-20 2015-09-30 Biosceptre International Limited Anti p2x7 receptor antibodies and fragments thereof
WO2011075789A1 (en) 2009-12-24 2011-06-30 Biosceptre International Limited Antibodies to non-functional oligomeric p2x7 receptors
EP2613808B1 (en) 2010-09-10 2017-11-08 Biosceptre (Aust) Pty Ltd Companion animal cancer treatments with an anti p2x7 antibody
MX349321B (en) 2011-07-01 2017-07-21 Biosceptre (Aust) Pty Ltd Combination therapy.
WO2014170343A1 (en) 2013-04-15 2014-10-23 Icm (Institut Du Cerveau Et De La Moelle Épinière) Depolarizing agents and nicotinic acetylcholine receptor modulators for treating dopaminergic-related disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0506032A1 (en) * 1991-03-28 1992-09-30 American Cyanamid Company Receptor purification method
US5360893A (en) * 1992-07-20 1994-11-01 University Of Colorado Foundation, Inc. DNA sequences encoding proteins used to elicit and detect programmed cell death

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2566595A (en) * 1994-05-27 1995-12-21 Glaxo Group Limited P-2x receptors (purinoceptor family)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0506032A1 (en) * 1991-03-28 1992-09-30 American Cyanamid Company Receptor purification method
US5360893A (en) * 1992-07-20 1994-11-01 University Of Colorado Foundation, Inc. DNA sequences encoding proteins used to elicit and detect programmed cell death

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BO X ET AL: "Solubilization and molecular size determination of the P2x purinoceptor from rat vas deferens.", J BIOL CHEM, SEP 5 1992, 267 (25) P17581-7, UNITED STATES *
OWENS, G.P. ET AL.;: "Identification of mRNAs associated with programmed cell death in immature thymocytes", MOLECULAR AND CELLULAR BIOLOGY, vol. 11, no. 8, pages 4177 - 4188 *
SIMON, JOSEPH ET AL: "Solubilization and molecular characterization of the P2X purinoceptor", BIOCHEM. SOC. TRANS., 1993, 200S *
VALERA S ET AL: "A new class of ligand-gated ion channel defined by P2x receptor for extracellular ATP.", NATURE, OCT 6 1994, 371 (6497) P516-9, ENGLAND *

Also Published As

Publication number Publication date
AU2566595A (en) 1995-12-21
WO1995033048A2 (en) 1995-12-07
EP0760850A1 (en) 1997-03-12
JPH10501122A (en) 1998-02-03
US5985603A (en) 1999-11-16
US6194162B1 (en) 2001-02-27

Similar Documents

Publication Publication Date Title
WO1995033048A3 (en) P2x receptors (purinoceptor family)
CA2140538A1 (en) Monoclonal antibodies that block ligand binding to the cd22 receptor in mature b cells
US4946788A (en) Purified immunoglobulin-related factor, novel monoclonal antibodies, hybridoma cell lines, processes and applications
DE68925226T2 (en) Monoclonal antibodies
CA2124126A1 (en) Monoclonal antibodies and fv specific for cd2 antigen
CA2021594A1 (en) Antibody to human interleukin-6 receptor
EP0394946A3 (en) Human monoclonal antibody, and its production and use
WO1989009621A3 (en) Compounds for diagnosis and/or therapy of tumours
CA2050910A1 (en) Human intra-acrosomal sperm antigen for use in a contraceptive vaccine
CA2203182A1 (en) Remedy for diseases caused by il-6 production
JP2002501085A5 (en)
CA2133106A1 (en) Monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon
EP0578774A4 (en) Monoclonal antibodies to stem cell factor receptors
CA2006332A1 (en) Method of detecting neurological disease or dysfunction
WO1989008460A1 (en) Antibodies for use in antilymphocyte antibody therapy
KR0181948B1 (en) Monoclonal Antibodies Against Human IgE
GR3003388T3 (en) Imidazolylguanidine derivatives, process for their preparation and medicines containing them
Piechaczyk et al. Production and characterization of monoclonal antibodies against human thyroglobulin
Daëron et al. 2.4 G2, a monoclonal antibody to macrophage Fcγ receptors, reacts with murine T cell Fcγ receptors and IgG‐binding factors
AU1046088A (en) Monoclonal antibody specific to neutrophils
NZ337601A (en) Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics by inhibiting IgE expression
EP1186301A3 (en) Monoclonal antibodies that recognize flk-2 receptors and the isolation of primitive hematopoietic stem cell populations
WO1996023884A3 (en) Human peroxisome proliferator activated receptors
AU5809290A (en) Monoclonal antibodies involved in alzheimer's disease, hybridomas secreting these monoclonal antibodies, antigen recognized by these antibodies, and their application
KR890700133A (en) Human monoclonal antibodies and agents for the prevention and treatment of infectious diseases containing them as active ingredients

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1995920076

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 08750134

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1995920076

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1995920076

Country of ref document: EP